Test Price
2,800 AEDโ Home Collection Available
BSCL2 Gene SPG17 (Hereditary Spastic Paraplegia Type 17) Genetic Test in UAE | 2,800 AED | NGS Full Gene Sequencing
Executive Summary & Core Metrics
This advanced genetic test employs next-generation sequencing (NGS) to analyze the entire coding region of the BSCL2 gene, delivering definitive detection of pathogenic variants linked to hereditary spastic paraplegia type 17 (SPG17). The service is fully compliant with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent follow Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO-accredited NGS processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM.
- Clinical Guidance: Telephonic post-test genetic counselling for comprehensive result interpretation.
- Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The BSCL2 Gene SPG17 Genetic Test provides high-resolution sequencing of all coding exons and flanking intronic regions of the BSCL2 gene using massively parallel next-generation sequencing technology. Bioinformatic analysis identifies single nucleotide variants, small insertions and deletions, and splice-site alterations with greater than 99.9% sensitivity. This method replaces traditional Sanger sequencing as the gold standard for definitive molecular diagnosis of hereditary spastic paraplegia type 17.
| Feature | Our Test (NGS Full Gene Sequencing) | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Precision | 99.9% sensitivity for SNVs & small indels across entire gene | ~95% sensitivity; limited to targeted exons only |
| Methodology | Massively parallel NGS with bioinformatic validation pipeline | Chain-termination (Sanger) sequencing, single-gene amplicons |
| Turnaround | 3 to 4 weeks | 4 to 6 weeks |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh (Consultant Medical Genetics, DHA Registration ID: 9294403) emphasizes: โThe BSCL2 SPG17 genetic test provides powerful diagnostic clarity for families affected by hereditary spastic paraplegia. A positive result must always be correlated with clinical presentation and family pedigree to guide prognosis and management. I recommend all patients complete pre-test genetic counselling to fully understand the implications of their results before proceeding with testing.โ
Medication Safety Advisory
โ ๏ธ Do Not Discontinue Prescribed Medication Without Medical Guidance
Never stop or alter any prescribed neurological medication without direct consultation with your treating physician. Genetic testing results complement, but do not replace, your current treatment plan. Abrupt changes to medication may cause serious adverse effects.
Exclusion Criteria & Emergency Red Flags
โ๏ธ Mandatory Pre-Test Requirements
- Exclusion: Testing of asymptomatic minors is prohibited without formal genetic counselling and legal guardian consent in accordance with UAE Federal Law No. 2 of 2019 and international medical ethics standards.
- Emergency Red Flags: Rapidly worsening muscle stiffness, frequent falls, acute urinary retention, or new-onset breathing difficulty warrant immediate neurological emergency evaluation.
- Pre-Test Requirement: A documented clinical history, neurological examination, and a dedicated genetic counselling session to chart family pedigree must precede sample collection.
Patient FAQ & Clinical Guidance
1. What does the BSCL2 SPG17 genetic test detect?
This test identifies disease-causing mutations in the BSCL2 gene responsible for hereditary spastic paraplegia type 17, enabling precise molecular diagnosis. Results clarify the genetic origin of progressive lower limb stiffness and weakness, guiding targeted therapies, prognosis, and family risk assessment. A positive result should be reviewed alongside clinical and family history data by a qualified medical geneticist.
2. What is the turnaround time and sample requirement?
The test requires 3 to 4 weeks from receipt of a simple peripheral blood sample collected in an EDTA tube (2โ3 mL whole blood). Alternative accepted matrices include extracted genomic DNA or a single blood spot on an FTA card. No fasting or special preparation is necessary; however, a prior genetic counselling session is mandatory to document family history and obtain informed consent.
3. Is insurance coverage available for this genetic test in the UAE?
Many UAE health insurers cover genetic testing for hereditary neurological disorders when medically indicated. Our team verifies your coverage directly via WhatsApp before sample collection. Contact +971 54 548 8731 for a quick pre-approval check, and we handle direct billing with your insurance provider whenever possible.
4. Can home collection be arranged for this test?
Yes, sample collection is available through our VIP Mobile Phlebotomy service. A certified phlebotomist visits your home between 8 AM and 11 PM daily, using temperature-controlled cold-chain transport to preserve sample integrity. This service is ideal for patients with mobility limitations or those who prefer the convenience of at-home testing.
UAE Regulatory & Data Privacy Adherence
๐ Your Data, Your Rights
DNA Labs UAE operates in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL), ensuring that all genetic information is collected, processed, stored, and shared solely with your explicit consent and for the intended diagnostic purpose. We adhere to Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields for secure health data exchange. All clinical procedures respect patient safety and consent requirements under Federal Decree-Law No. 4 of 2016 on Medical Liability. Your genetic data will never be disclosed to third parties without your written authorization.
Clinical & Logistical Metadata
| Test Name | BSCL2 Gene SPG17 (Hereditary Spastic Paraplegia Type 17) Genetic Test โ NGS Full Gene Sequencing |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 to 4 weeks from receipt of specimen |
| Sample Type / Matrix | Peripheral whole blood (EDTA tube), extracted genomic DNA, or FTA card blood spot |
| Methodology Used | Next-Generation Sequencing (NGS) โ full coding region and flanking intronic regions with bioinformatic variant calling |
| ICD-10-CM Code | G11.4 (Hereditary Spastic Paraplegia), Z13.71 (Encounter for genetic testing for nervous system disorder) |
| LOINC Code | 21665-9 (Sequencing analysis short variant identification) |
| DHA Facility License & Laboratory Address Invariants | DHA Facility License Number: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | Corporate Lab Branding: DNA Labs UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians